Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium

被引:0
|
作者
Eline Vandael
Thomas Marynissen
Johan Reyntens
Isabel Spriet
Joris Vandenberghe
Rik Willems
Veerle Foulon
机构
[1] KU Leuven – University of Leuven,Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy
[2] KU Leuven – University of Leuven,Department of Cardiovascular Sciences
[3] University Hospitals Leuven,Cardiology
[4] Sint-Jan Hospital,Pharmacy Department
[5] University Hospitals Leuven,Department of Neurosciences
[6] KU Leuven – University of Leuven,Psychiatry
[7] University Hospitals Leuven,undefined
关键词
Antidepressants; Antipsychotics; Belgium; Drug-induced QT-prolongation; Drug interactions; Psychiatry; Torsade de pointes;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction Drug-induced QT-prolongation is an established risk factor for Torsade de pointes and sudden cardiac death. The list of QT-prolonging drugs is extensive and includes many drugs commonly used in psychiatry. Aim In this study we performed a cross-sectional analysis of medication profiles to assess the prevalence of drug interactions potentially leading to QT-prolongation. Setting 6 psychiatric hospitals in Flanders, Belgium. Methods For each patient, the full medication list was screened for the presence of interactions, with special attention to those with an increased risk for QT-prolongation. Current practice on QT monitoring and prevention of drug-induced arrhythmia was assessed. Main outcome measure Number of drug interactions with risk of QT-prolongation. Results 592 patients (46 % female; mean age 55.7 ± 17.1 years) were included in the analysis. 113 QT-prolonging interactions were identified in 43 patients (7.3 %). QT-prolonging interactions occurred most frequently with antidepressants (n = 102) and antipsychotics (n = 100). The precautions and follow-up provided by the different institutions when combining QT-prolonging drugs were very diverse. Conclusion Drug combinations that are associated with QT-prolongation are frequently used in the chronic psychiatric setting. Persistent efforts should be undertaken to provide caregivers with clear guidelines on how to use these drugs in a responsible and safe way.
引用
收藏
页码:757 / 765
页数:8
相关论文
共 50 条
  • [1] Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium
    Vandael, Eline
    Marynissen, Thomas
    Reyntens, Johan
    Spriet, Isabel
    Vandenberghe, Joris
    Willems, Rik
    Foulon, Veerle
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (04) : 757 - 765
  • [2] QT-INTERVAL PROLONGING DRUGS - MECHANISMS AND CLINICAL RELEVANCE OF THEIR ARRHYTHMOGENIC HAZARDS
    ZEHENDER, M
    HOHNLOSER, S
    JUST, H
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 (02) : 515 - 530
  • [3] Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs
    Pezo, Rossanna C.
    Yan, Andrew T.
    Earle, Craig
    Chan, Kelvin K.
    HEART, 2019, 105 (21) : 1649 - 1655
  • [4] Utility of the embryonic chick ventricle as a new model to detect QT-interval prolonging drugs
    Namekata, I.
    Takahara, A.
    Nouchi, H.
    Kimata, M.
    Tsuruoka, N.
    Shigenobu, K.
    Tanaka, H.
    HEART, 2008, 94 (02)
  • [5] Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients
    Schaechtele, Simone
    Tuemena, Thomas
    Gassmann, Karl-Guenter
    Fromm, Martin F.
    Maas, Renke
    PLOS ONE, 2016, 11 (05):
  • [6] Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients
    Freeman, Bradley D.
    Dixon, David J.
    Coopersmith, Craig M.
    Zehnbauer, Barbara A.
    Buchman, Timothy G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (10) : 971 - 981
  • [7] New proarrhythmia model of monkey can qualitatively and quantitatively predict clinical risks of QT-interval prolonging drugs
    Takahara, Akira
    Sakamoto, Kengo
    Sugiyama, Atsushi
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 41 (06) : 1073 - 1073
  • [8] Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
    Michel, Holger
    Potapow, Antonia
    Dechant, Markus-Johann
    Brandstetter, Susanne
    Wellmann, Sven
    Koeninger, Angela
    Melter, Michael
    Apfelbacher, Christian
    Kabesch, Michael
    Gerling, Stephan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Extent of use of QT interval prolonging medication in Psychiatry In-Patient in a tertiary care hospital
    Sarkar, C.
    Nongpiur, A.
    Wahlang, J.
    Das, B.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S66 - S66
  • [10] Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries
    De Ponti, F
    Poluzzi, E
    Vaccheri, A
    Bergman, U
    Bjerrum, L
    Ferguson, J
    Frenz, KJ
    McManus, P
    Schubert, I
    Selke, G
    Terzis-Vaslamatzis, G
    Montanaro, N
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (02) : 171 - 177